To maintain IFN-γ induction by recombinant human interleukin-12 (rhIL-12) and enhance its activity against melanoma and renal cell cancer, rhIL-12 was combined with IL-2 in a phase I dose escalation study [99]. The gene discussed is IFNG; the disease is melanoma.